Target intelligence / Profile preview

Human serum albumin copper binding (N-terminal ATCUN site) (HSA Cu(II)-binding site (ATCUN))

Target
HSA Cu(II)-binding site (ATCUN)
Molecular classification
Other
01

Overview

Human serum albumin (HSA) is the principal extracellular carrier of exchangeable Cu(II) in blood and binds copper mainly at its N-terminal ATCUN site, contributing substantially to the plasma Cu(II) pool and delivery to tissues[6]. Hepatocytes and other cells take up copper from Cu–albumin; evidence indicates cells recognize Cu–albumin and may preferentially bind a ternary Cu–albumin–histidine complex before releasing albumin/histidine and transporting copper across the membrane[2][5]. In pharmacology, HSA’s labile Cu(II) pool serves as a metal source for certain anticancer thiosemicarbazones, which chelate Cu(II) from HSA’s N-terminus and can form ternary conjugates with HSA, affecting drug activity and behavior[8][4]. Numerous synthetic Cu(II) complexes and chelators interact with serum albumin, with binding often occurring at defined albumin drug-binding sites and influencing complex stability and protein structure[1][3]. Overall, “albumin–copper complex formation” describes a physiological carrier–metal interaction rather than a discrete drug target, but it is crucial for copper homeostasis and can modulate the pharmacology of copper-interacting therapeutics[6][8][5][2][1][3].

Other names
Albumin–copper complexCopper–albumin complexCu(II)–human serum albumin complexCu–HSA complexN-terminal copper and nickel binding site of albumin (ATCUN/NSI)
02

Mechanism of action

For thiosemicarbazones: chelation of Cu(II) from the N-terminal Cu-binding site of HSA, formation of Cu(II)–TSC complexes and ternary HSA conjugates (likely via histidine), influencing anticancer activity and pharmacology[8][4]. Cellular uptake context: cells recognize Cu–albumin and preferentially a ternary Cu–albumin–histidine complex; albumin/histidine are released and copper is transported across the membrane after binding to the cell surface[2]. Multiple routes for cellular acquisition of copper from albumin and α2-macroglobulin; hepatic uptake partly via CTR1 for α2-macroglobulin, with additional unidentified systems for albumin-derived copper[5].

03

Biological functions

Copper transport in blood plasma[6]Delivery of copper to cells, including hepatocytes, via Cu–albumin and ternary Cu–albumin–histidine complexes[2][5]Reservoir for the labile extracellular Cu(II) pool available to small-molecule chelators[6][8]
04

Disease associations

OtherDisturbances of systemic copper metabolism (e.g., Wilson’s and Menkes diseases) involve altered distribution among serum carriers including albumin[6]Potential modulation of cancer pharmacology via serum copper availability to anticancer chelators[8][4]
05

Safety considerations

Off-target binding of investigational copper complexes to albumin can alter distribution, efficacy, and potentially toxicity profiles[1][3]Drug–protein interactions that mobilize copper from HSA may impact systemic copper homeostasis and interact with disorders of copper metabolism[6][8]Competition among metals or drugs for albumin binding sites may affect copper uptake kinetics and drug effects[5][6]
06

Interacting drugs

Thiosemicarbazones (e.g., Triapine, Dp44mT, Me2NNMe2) that can extract Cu(II) from HSA’s N-terminal site and form Cu–drug complexes[8][4]

1 more in the full profile.

07

Biomarkers

Serum copper distribution among carriers (albumin, ceruloplasmin, α2-macroglobulin) as indicators of copper status and disturbances in copper metabolism[6]Labile serum Cu(II) bound to HSA as a pharmacologically relevant pool affecting response to copper-chelating anticancer agents[8]

Beyond the preview

Go deeper on Human serum albumin copper binding (N-terminal ATCUN site) (HSA Cu(II)-binding site (ATCUN)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Human serum albumin copper binding (N-terminal ATCUN site) (HSA Cu(II)-binding site (ATCUN)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call